PHERGain reports 92.4% 5-year invasive disease-free survival in chemotherapy-free subgroup

Among 86 women who met imaging and surgical response criteria and received no chemotherapy in the PHERGain trial, 5-year invasive disease-free survival was 92.4%. That measure tracks survival without invasive cancer events. After a median follow-up of 5.6 years, the subgroup had one distant recurrence. The researchers cautioned that these outcomes describe a subgroup selected by its response to treatment; they do not establish the causal effect of omitting chemotherapy.
PHERGain was a randomized, non-comparative phase 2 trial in HER2-positive early breast cancer, meaning it assigned patients to treatment groups but was not designed to compare those groups directly. Eligible women had operable cancer at stages I to IIIA, with tumors measuring at least 1.5 cm.
Group A received chemotherapy plus trastuzumab and pertuzumab, medicines that target HER2. Group B began treatment with trastuzumab and pertuzumab, with or without endocrine therapy, which acts on hormone signaling.
For group B, the next treatment decision depended on a PET scan after two cycles. This scan uses a radioactive glucose tracer to assess response. Treatment also depended on pathological complete response, meaning no remaining invasive cancer was found in tissue examined after surgery. Patients who did not respond on the scan or did not achieve pathological complete response received chemotherapy.
Across all 267 women in group B, 5-year invasive disease-free survival was 89.5%, with a 95% confidence interval of 85.7 to 93.4. For the 86 women who responded on imaging and achieved pathological complete response without chemotherapy, the 95% confidence interval was 86.7 to 98.5. These intervals express uncertainty around the survival estimates.
The researchers also examined circulating tumor DNA, fragments of tumor genetic material found in blood. These analyses were exploratory. Detectable tumor DNA before or during treatment was associated with poorer invasive disease-free survival. When that DNA cleared from the blood, patients had higher rates of pathological complete response and better long-term outcomes.
The researchers said the findings continued to support adapting chemotherapy decisions to imaging and tissue response in HER2-positive early breast cancer. The blood analyses also suggested a potential role for circulating tumor DNA in tailoring treatment.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].